XSHE000999
Market cap8.14bUSD
Dec 25, Last price
46.67CNY
1D
0.67%
1Q
16.03%
Jan 2017
88.23%
Name
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Chart & Performance
Profile
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in the People's Republic of China and internationally. It also provides related health services. The company offers OTC products, including cold, skin, gastrointestinal, cough relieving, orthopedics, and pediatrics drugs; prescription drug products in traditional Chinese medicine, tumors, cardiovascular and cerebrovascular, digestive system, orthopedics, and pediatrics; Chinese medicine injections; formula granules; and anti-infective drugs. It sells its products under 999 family medicine brands, Sanjiuweitai series, 999 Ganmaoling series, 999 dermatitis series, and other products. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. The company was founded in 1999 and is based in Shenzhen, the People's Republic of China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources (Holdings) Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 24,738,963 36.83% | 18,079,461 18.01% | 15,319,994 12.34% | |||||||
Cost of revenue | 18,517,953 | 14,237,691 | 12,006,165 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 6,221,011 | 3,841,771 | 3,313,828 | |||||||
NOPBT Margin | 25.15% | 21.25% | 21.63% | |||||||
Operating Taxes | 580,975 | 466,425 | 348,219 | |||||||
Tax Rate | 9.34% | 12.14% | 10.51% | |||||||
NOPAT | 5,640,036 | 3,375,345 | 2,965,609 | |||||||
Net income | 2,852,932 16.50% | 2,448,802 19.16% | 2,055,104 28.65% | |||||||
Dividends | (1,055,918) | (841,854) | (496,138) | |||||||
Dividend yield | 1.66% | 1.84% | 1.48% | |||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 885,651 | 235,092 | 110,716 | |||||||
Long-term debt | 2,041,955 | 261,859 | 185,382 | |||||||
Deferred revenue | 455,501 | 423,190 | 395,128 | |||||||
Other long-term liabilities | 676,377 | 119,688 | 129,148 | |||||||
Net debt | (6,024,120) | (5,600,854) | (3,987,782) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 4,220,402 | 3,006,375 | 1,870,516 | |||||||
CAPEX | (857,211) | |||||||||
Cash from investing activities | (821,735) | |||||||||
Cash from financing activities | 450,425 | |||||||||
FCF | 1,639,863 | 2,918,724 | 1,968,763 | |||||||
Balance | ||||||||||
Cash | 8,226,787 | 3,149,709 | 4,283,880 | |||||||
Long term investments | 724,938 | 2,948,096 | ||||||||
Excess cash | 7,714,777 | 5,193,832 | 3,517,880 | |||||||
Stockholders' equity | 21,908,937 | 15,946,697 | 14,089,849 | |||||||
Invested Capital | 20,031,567 | 12,755,444 | 12,552,567 | |||||||
ROIC | 34.40% | 26.67% | 25.37% | |||||||
ROCE | 22.15% | 21.15% | 20.37% | |||||||
EV | ||||||||||
Common stock shares outstanding | 1,278,900 | 978,900 | 978,900 | |||||||
Price | 49.73 6.24% | 46.81 36.71% | 34.24 37.29% | |||||||
Market cap | 63,599,717 38.80% | 45,822,309 36.71% | 33,517,536 37.29% | |||||||
EV | 62,870,329 | 40,745,236 | 29,959,966 | |||||||
EBITDA | 7,017,678 | 4,364,512 | 3,790,025 | |||||||
EV/EBITDA | 8.96 | 9.34 | 7.90 | |||||||
Interest | 85,174 | 21,227 | 13,267 | |||||||
Interest/NOPBT | 1.37% | 0.55% | 0.40% |